IMM
Immutep Ltd
Biotechnology
·
Healthcare
11
comments
6
fund managers
past 90 days
About Immutep Ltd
Immutep Ltd. (founded 1987) is a clinical-stage biotechnology company headquartered in Sydney, Australia. The firm specializes in developing LAG-3 immunotherapeutic products for treating cancer and autoimmune diseases. Its core clinical pipeline features four key assets: eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). Immutep focuses on advancing these LAG-3 related therapies through clinical trials to address unmet medical needs in oncology and immunology.
Commentary Volume
11
Comments
6
Fund managers
0
Past 90 days
SOURCE
ACTION
COMMENT PREVIEW
FUND MANAGER
DATE
Loading...
.
Loading...
Loading...
Loading...
Loading...
Source: Ipsum Capital Q4 Quarterly Letter · Published 14 March 2025
Report a problem
Loading...
.
Loading...
Loading...
Loading...
Loading...
§ Important Notice
The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Commentary
Sector
Healthcare
Market cap
$88M
Fund managers
6 managers
First covered
31 Dec 2023
Last updated
31 Mar 2026
Company Details
Related Themes
ic
Ipsum Capital
6 comments
ic
Amet Funds
4 comments
ic
Dolor
3 comments
Top Investors Covering MIN
§ Reminder
The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Frequently asked questions about Immutep Ltd (ASX:IMM)
Frequently asked questions
Who is investing in Immutep Ltd (ASX:IMM)?
Fund managers including Pengana Capital Group, Perennial Partners, Perennial Value Management, Cyan Investment Management, Pengana Capital and Renaissance Asset Management have invested in Immutep Ltd (ASX:IMM).
What is the short interest in Immutep Ltd (ASX:IMM)?
The short interest in Immutep Ltd (ASX:IMM) is 2.19% which makes it the 121st most shorted stock on the ASX. Of the 1.5B shares that Immutep Ltd has on issue, 32.3M have been sold short.
What does Immutep Ltd (ASX:IMM) do?
Immutep Ltd. (founded 1987) is a clinical-stage biotechnology company headquartered in Sydney, Australia. The firm specializes in developing LAG-3 immunotherapeutic products for treating cancer and autoimmune diseases. Its core clinical pipeline features four key assets: eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). Immutep focuses on advancing these LAG-3 related therapies through clinical trials to address unmet medical needs in oncology and immunology.
Loading...